Form 4: HALO Director Sells Shares Under 10b5-1 Plan

HALOZYME THERAPEUTICS Director Bernadette Connaughton sold 2,000 shares of common stock for $68.48 per share, reducing her direct beneficial ownership to 42,952 shares.

Summary

• Bernadette Connaughton, a Director of HALOZYME THERAPEUTICS, INC. (HALO), reported a sale of common stock.
• The transaction involved the disposition of 2,000 shares of common stock.
• The shares were sold at a price of $68.48 per share.
• The sale was executed on November 10, 2025.
• Following this transaction, Bernadette Connaughton directly beneficially owns 42,952 shares of common stock.
• The sale was made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction (sale of shares) conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates personal financial planning rather than a reaction to new company-specific information.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a routine disclosure requirement for directors' stock transactions.

Stakeholder Impact

• Shareholders: A director's sale of shares, especially under a 10b5-1 plan, is generally not considered a significant indicator of future company performance but is noted for transparency in insider holdings.

Key Dates

Keywords

HALOZYME THERAPEUTICS, HALO, Form 4, Insider Trading, Stock Sale, Director, Bernadette Connaughton, 10b5-1 Plan